Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA TAXANE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL_ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
6.1 CONCLUSION
7 NORTH AMERICA TAXANE MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 THE RISE IN INCIDENCE OF CANCER
8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT
8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS
8.1.4 USE OF REIMBURSEMENT FOR TAXANE
8.2 RESTRAINTS
8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS
8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT
8.2.3 RISE IN PRODUCT RECALLS
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT
8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT
9 NORTH AMERICA TAXANE MARKET, BY TYPE
9.1 OVERVIEW
9.2 PACLITAXEL
9.2.1 BY TYPE
9.2.1.1 SEMI-SYNTHETIC
9.2.1.2 NATURAL
9.2.2 BY STRENGTH
9.2.2.1 100MG
9.2.2.2 200MG
9.2.2.3 250MG
9.2.2.4 30MG
9.2.2.5 260MG
9.2.2.6 300MG
9.3 DOCETAXEL
9.3.1 120MG
9.3.2 80MG
9.3.3 20MG
9.3.4 40MG
9.3.5 60MG
9.4 CABAZITAXEL
9.4.1 60MG
10 NORTH AMERICA TAXANE MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 BREAST CANCER
10.3 NON-SMALL CELL LUNG CANCER
10.4 PANCREATIC CANCER
10.5 OVARIAN CANCER
10.6 PROSTATE CANCER
10.7 OTHERS
11 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE
11.1 OVERVIEW
11.2 GENERICS
11.3 BRANDED
12 NORTH AMERICA TAXANE MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 LIPOSOMES
12.3 NANOPARTICLES
12.4 POLYMERIC MICELLES
12.5 OTHERS
13 NORTH AMERICA TAXANE MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.2.1 FEMALE
13.2.2 MALE
13.3 GERIATRIC
13.3.1 FEMALE
13.3.2 MALE
14 NORTH AMERICA TAXANE MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 AMBULATORY SURGICAL CENTERS
14.4 SPECIALTY CLINICS
14.5 OTHERS
15 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 RETAIL SALES
15.2.1 HOSPITAL PHARMACY
15.2.2 RETAIL PHARMACY
15.2.3 ONLINE PHARMACY
15.3 DIRECT TENDER
16 NORTH AMERICA TAXANE MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA TAXANE MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 BRISTOL-MYERS SQUIBB COMPANY
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 SANOFI-AVENTIS U.S. LLC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA )
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 HIKMA PHARMACEUTICALS PLC
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 ACCORD HEALTHCARE
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 AQVIDA GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 AUREATE HEALTHCARE
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 DR. REDDY’S LABORATORIES LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 ELEVAR THERAPEUTICS
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENTS
19.13 HETERO HEALTHCARE LIMITED.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 HUIANG PHARMACEUTICAL CO LTD
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 INGENUS PHARMACEUTICALS, LLC
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 LUYE PHARMA GROUP
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 PANACEA BIOTEC
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 RPG LIFE SCIENCES LIMITED
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SAMARTH LIFE SCIENCES PVT. LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 SAMYANG HOLDINGS CORPORATION.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 TORRENT PHARMACEUTICALS LTD
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
19.24 TAXANE HEALTHCARE
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA CABAZITAXEL IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA CABAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA BREAST CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA NON-SMALL LUNG CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA PANCREATIC CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA OVARIAN CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA PROSTATE CANCER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA GENERICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA BRANDED IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA LIPOSOMES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA NANOPARTICLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA POLYMERIC MICELLES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA ADULT IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA HOSPITALS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA SPECIALTY CLINICS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA OTHERS IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA DIRECT TENDER IN TAXANE MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA TAXANE MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 46 NORTH AMERICA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 47 NORTH AMERICA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 50 NORTH AMERICA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 U.S. TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 U.S. PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 U.S. TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 U.S. TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 57 U.S. TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 U.S. PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 59 U.S. DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 60 U.S. CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 61 U.S. TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 62 U.S. ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 63 U.S. GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 64 U.S. TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 U.S. TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 U.S. RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 CANADA TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 CANADA PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 CANADA TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 CANADA TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 71 CANADA TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 72 CANADA PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 73 CANADA DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 74 CANADA CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 75 CANADA TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 76 CANADA ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 77 CANADA GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 78 CANADA TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 CANADA TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 80 CANADA RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 81 MEXICO TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 MEXICO PACLITAXEL IN TAXANE MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 MEXICO TAXANE MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 MEXICO TAXANE MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 85 MEXICO TAXANE MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 86 MEXICO PACLITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 87 MEXICO DOCETAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 88 MEXICO CARBAZITAXEL IN TAXANE MARKET, BY STRENGTH, 2020-2029 (USD MILLION)
TABLE 89 MEXICO TAXANE MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 90 MEXICO ADULT IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 91 MEXICO GERIATRIC IN TAXANE MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 92 MEXICO TAXANE MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 MEXICO TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 MEXICO RETAIL SALES IN TAXANE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA TAXANE MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA TAXANE MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA TAXANE MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA TAXANE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA TAXANE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA TAXANE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA TAXANE MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA TAXANE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA TAXANE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA TAXANE MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA TAXANE MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING INVESTMENT FOR HEALTHCARE INFRASTRUCTURE IS EXPECTED TO DRIVE THE NORTH AMERICA TAXANE MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA TAXANE MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA TAXANE MARKET
FIGURE 15 INCIDENCE OF BREAST CANCER IN 2020
FIGURE 16 NORTH AMERICA TAXANE MARKET: BY TYPE, 2021
FIGURE 17 NORTH AMERICA TAXANE MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 NORTH AMERICA TAXANE MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA TAXANE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA TAXANE MARKET: BY APPLICATION, 2021
FIGURE 21 NORTH AMERICA TAXANE MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 22 NORTH AMERICA TAXANE MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA TAXANE MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, 2021
FIGURE 25 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)
FIGURE 26 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA TAXANE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA TAXANE MARKET: BY FORMULATION, 2021
FIGURE 29 NORTH AMERICA TAXANE MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 NORTH AMERICA TAXANE MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA TAXANE MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, 2021
FIGURE 33 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 34 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 35 NORTH AMERICA TAXANE MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 36 NORTH AMERICA TAXANE MARKET: BY END USER, 2021
FIGURE 37 NORTH AMERICA TAXANE MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 38 NORTH AMERICA TAXANE MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 NORTH AMERICA TAXANE MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 42 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 NORTH AMERICA TAXANE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 NORTH AMERICA TAXANE MARKET: SNAPSHOT (2021)
FIGURE 45 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2021)
FIGURE 46 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 NORTH AMERICA TAXANE MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 NORTH AMERICA TAXANE MARKET: BY TYPE (2022-2029)
FIGURE 49 NORTH AMERICA TAXANE MARKET: COMPANY SHARE 2021 (%)
